IMNM - NASDAQ

Immunome, Inc.

IMNM·NASDAQ

$19.78

-0.15%

HealthcareBiotechnology

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.89B

EPS-2.4300

P/E Ratio-8.14

Earnings Date08/05/2026

imnm

Total Stockholders' Equity

Last Annual Value

634.34M

3-Year CAGR

236%

5-Year CAGR

73%

10-Year CAGR

39%

Adjust for Inflation

Immunome, Inc. Competitors Analysis of Total Stockholders' Equity

IMNM · NASDAQ

Company	Total Stockholders' Equity	CAGR 3Y	CAGR 5Y	CAGR 10Y
Immunome, Inc. NASDAQ:IMNM	634.34M	74.3%	67.4%	N/A
Zenas BioPharma, Inc. NASDAQ:ZBIO	242.14M	N/A	N/A	N/A
Intellia Therapeutics, Inc. NASDAQ:NTLA	671.39M	-13.9%	-8.4%	12.3%
Upstream Bio, Inc. NASDAQ:UPB	469.85M	N/A	N/A	N/A
Maze Therapeutics, Inc. NASDAQ:MAZE	354.97M	228.1%	N/A	N/A
Celldex Therapeutics, Inc. NASDAQ:CLDX	527.16M	7.1%	4.7%	7.1%
Vera Therapeutics, Inc. NASDAQ:VERA	604.52M	81.2%	54.1%	N/A
Biohaven Ltd. NYSE:BHVN	52.07M	-50.4%	8.5%	N/A
Spyre Therapeutics, Inc. NASDAQ:SYRE	715.24M	57.2%	53.5%	27.5%

Immunome, Inc. Fair Value Envelope

IMNM · NASDAQ

Our analysis suggests that IMNM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $19.78, this represents a potential HIDDEN relative to our calculated worth for Immunome, Inc..

HIDDEN

Intrinsic Value

Current Price: $19.78

Related Guides

Blog Categories

Continue your IMNM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.